Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Treatment profile of hepatitis C patients - a comparison of interferon alpha 2a and 2b treatment regimes.

Aziz S, Qamar R, Ahmed I, Imran K, Masroor M, Rajper J, Nafay S, Noorulain W, Khan MH.

J Coll Physicians Surg Pak. 2010 Sep;20(9):581-5. doi: 09.2010/JCPSP.581585.

PMID:
20810048
2.

End treatment response and sustained viral response in hepatitis C virus genotype 3 among Pakistani population.

Amir M, Rahman AS, Jamal Q, Siddiqui MA.

Ann Saudi Med. 2013 Nov-Dec;33(6):555-8. doi: 10.5144/0256-4947.2013.555.

4.

Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.

Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S.

J Clin Gastroenterol. 2010 Feb;44(2):140-5. doi: 10.1097/MCG.0b013e3181ba9992.

PMID:
19826275
5.

Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.

Tomimatsu M, Aizawa Y, Chuganji Y, Ishizuka H, Fujita Y, Aizawa R, Abe H, Matsuda T, Itou Y, Nakanishi H, Ushiyama H, Higuchi T, Fujimoto T, Endou H, Iga D, Ohta K, Kuroda H.

J Gastroenterol Hepatol. 2006 Jul;21(7):1177-83.

PMID:
16824072
6.

A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P.

Clin Ther. 2010 Aug;32(9):1565-77. doi: 10.1016/j.clinthera.2010.08.009. Review.

PMID:
20974315
7.

Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.

Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, Angarano G.

J Interferon Cytokine Res. 2008 Oct;28(10):623-9. doi: 10.1089/jir.2007.0116.

PMID:
18778199
8.

Treatment outcome of HCV infected paediatric patients and young adults at Karachi, Pakistan.

Aziz S, Rajper J, Noorulain W.

J Ayub Med Coll Abbottabad. 2012 Jul-Dec;24(3-4):56-8.

PMID:
24669610
9.

Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.

Pérez R, Jiménez M, Crespo J, Diago M, Enríquez J, Vaquero P, Solá R, Olcoz JL, Romero M, Salmerón J, Blanco MI, Oña M, Melón S, Rodrigo L; Grupo Inter-Hospitalario Español.

J Viral Hepat. 2003 Nov;10(6):437-45.

PMID:
14633177
10.

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS.

J Viral Hepat. 2005 May;12(3):283-91.

PMID:
15850469
11.

Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.

Belhadj N, Houissa F, Elloumi H, Ouakaa A, Gargouri D, Romani M, Kilani A, Kochlef A, Kharrat J, Ghorbel A.

Tunis Med. 2008 Apr;86(4):341-5.

PMID:
19476135
12.
13.

Response to standard interferon A2b and ribavirin combination therapy in chronic hepatitis C treatment naive patients.

Jadoon SM, Jadoon S, Muhammad I.

J Ayub Med Coll Abbottabad. 2010 Oct-Dec;22(4):164-6.

PMID:
22455288
14.

[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].

Cheong HR, Woo HY, Heo J, Yoon KT, Kim DU, Kim GH, Kang DH, Song GA, Cho M.

Korean J Hepatol. 2010 Mar;16(1):38-48. doi: 10.3350/kjhep.2010.16.1.38. Korean.

PMID:
20375641
16.

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J.

Am J Gastroenterol. 2004 Aug;99(8):1490-6.

PMID:
15307866
17.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
18.

Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.

Czerwionka-Szaflarska M, Chrobot A, Szaflarska-Szczepanik A.

Med Sci Monit. 2000 Sep-Oct;6(5):964-70.

PMID:
11208439
19.

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, Cela M, Piattelli M, Annese M, Maio G, Conte D, Guadagnino V, Pazienza V, Festi D, Spirito F, Andriulli A.

J Viral Hepat. 2005 May;12(3):292-9.

PMID:
15850470
20.

A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.

Yao GB, Fu XX, Tian GS, Xu DZ, Hao LJ, Huangfu YS, Su CX.

J Gastroenterol Hepatol. 2000 Oct;15(10):1165-70.

PMID:
11106097

Supplemental Content

Support Center